CME

Faculty: Linda Stein Gold, MD Faculty: Bruce Strober, MD, PhD This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new...

Faculty: Jörg Latus, MD Faculty: Jürgen Floege, MD Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria...

Faculty: Scott Solomon, MD Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve...

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents...

Faculty: Joyce F. Liu, MD, MPH Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to...

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents...

Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Faculty: Javed Butler, MD Faculty: Stephen J. Greene, MD, FACC, FHFSA For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despite the use of...

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents...

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents...

Faculty: Naim Alkhouri, MD, FAASLD, DABOM Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify cirrhosis and clinically...